Preferred Label : Vutrisiran;
UNII : GB4I2JI8UI;
CAS number : 1867157-35-4;
Molecule name : ALN-TTRSC02;
NCI Metathesaurus CUI : CL554251;
Origin ID : C152919;
UMLS CUI : C5446328;
Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_salt_form
- is_free_acid_or_base_form_of
https://ansm.sante.fr/tableau-acces-derogatoire/vutrisiran
2025
false
false
false
France
French
Vutrisiran
drug information
amyloidosis, hereditary, Transthyretin-Related
vutrisiran
---
https://www.has-sante.fr/jcms/p_3482344/fr/amvuttra-vutrisiran-amylose-hereditaire-a-transthyretine
2023
false
false
false
France
RNAi Therapeutics
treatment outcome
insurance, health, reimbursement
vutrisiran
injections, subcutaneous
amyloid neuropathies, familial
adult
polyneuropathies
evaluation of the transparency committee
amyloidosis, hereditary, Transthyretin-Related
Vutrisiran
---
https://www.has-sante.fr/jcms/p_3402366/fr/amvuttra-vutrisiran-amylose-hereditaire-a-transthyretine
2023
false
false
false
France
vutrisiran
treatment outcome
insurance, health, reimbursement
Vutrisiran
rna, small interfering
injections, subcutaneous
adult
RNAi Therapeutics
amyloid neuropathies, familial
evaluation of the transparency committee
amyloidosis, hereditary, Transthyretin-Related
---
https://www.has-sante.fr/jcms/p_3395907/fr/amvuttra-vutrisiran-amylose-hereditaire-a-transthyretine
2022
false
false
false
France
Vutrisiran
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
orphan drug production
polyneuropathies
vutrisiran
evaluation of the transparency committee
amyloidosis, hereditary, Transthyretin-Related
---
https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Vutrisiran
Vutrisiran
orphan drug production
vutrisiran
amyloidosis, hereditary, Transthyretin-Related
adult
injections, subcutaneous
product surveillance, postmarketing
RNAi Therapeutics
pregnancy
breast feeding
rna, small interfering
drug evaluation, preclinical
---
